{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:03:14Z","timestamp":1793106194311,"version":"4.5.0"},"reference-count":116,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Black individuals have higher incidence and mortality rates of prostate cancer than White individuals, and existing literature on treatment sequencing strategies in metastatic castration-resistant prostate cancer (mCRPC) is limited and conflicting. Understanding the interplay between race and treatment could optimize care and improve overall survival (OS).\n                    <jats:bold>Methods:<\/jats:bold>\n                    This retrospective observational cohort study assessed survival outcomes based on race and initial androgen receptor pathway inhibitor (ARPI) treatment among veterans with mCRPC. Participants included White or Black veterans diagnosed with mCRPC between January 1, 2011, and March 12, 2024, initially treated with either abiraterone or enzalutamide. The primary outcome was OS measured from the date of diagnosis and from the start of initial therapy. Kaplan-Meier estimates and Cox proportional hazards models were used to evaluate outcome differences by race and treatment.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 12,355 patients met eligibility criteria. The mean age of the cohort was 74.57 years, with Black patients diagnosed approximately 4 years younger than White patients (71.77 vs 75.60, respectively;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001). Median prostate-specific antigen and mean Charlson comorbidity index scores were higher among Black patients. Median OS was higher in Black patients compared with White patients (36.3 months [95% CI, 35\u201338] vs 31 months [95% CI, 30.3\u201331.7], respectively; inverse probability of treatment weighting hazard ratio [IPTW HR], 0.80;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.0001) Median OS was also longer among patients prescribed enzalutamide compared with those prescribed abiraterone (28 months [95% CI, 27.0\u201328.9] vs 23.7 months [95% CI, 23.1\u201324.2], respectively; IPTW HR, 1.14;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.0001). No significant race-by-treatment interaction was observed.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Black veterans with prostate cancer treated with ARPIs lived approximately 6 months longer after developing mCRPC but had a shorter lifespan\u2014by about 3 years\u2014compared with White patients. Differences in tumor biology may help explain why Black individuals develop prostate cancer at a younger age and exhibit better responses to cancer therapy.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2025.7078","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:56:22Z","timestamp":1765979782000},"page":"507-515","source":"Crossref","is-referenced-by-count":2,"title":["The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.6004","volume":"23","author":[{"given":"Danielle","family":"Candelieri-Surette","sequence":"first","affiliation":[{"name":"University of Massachusetts Lowell, Lowell, MA"},{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Cheranda","sequence":"additional","affiliation":[{"name":"Medicine Service, St. Louis Veterans Affairs Health Care System, St. Louis, MO"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JongSoo","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Massachusetts Lowell, Lowell, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Pimentel","sequence":"additional","affiliation":[{"name":"University of Massachusetts Lowell, Lowell, MA"},{"name":"Center for Healthcare Organization and Implementation Research, Department of Veterans Affairs, Bedford Healthcare System, Bedford, MA"},{"name":"New England Geriatric Research Education and Clinical Center, Department of Veterans Affairs, Bedford Healthcare System, Bedford, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Lynch","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Berlowitz","sequence":"additional","affiliation":[{"name":"University of Massachusetts Lowell, Lowell, MA"},{"name":"Boston University School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Schoen","sequence":"additional","affiliation":[{"name":"Medicine Service, St. Louis Veterans Affairs Health Care System, St. Louis, MO"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Key statistics for prostate cancer.","unstructured":"American Cancer Society. Key statistics for prostate cancer. Accessed June 10, 2025. Available at: https:\/\/www.cancer.org\/cancer\/types\/ prostate-cancer\/about\/key-statistics.html"},{"key":"B2","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"1740","article-title":"Cancer incidence in the U.S. military population: comparison with rates from the SEER program","volume":"18","author":"Zhu K","year":"2009","unstructured":"Zhu K, Devesa SS, Wu H,  Cancer incidence in the U.S. military population: comparison with rates from the SEER program. Cancer Epidemiol Biomarkers Prev 2009;18:1740\u20131745."},{"key":"B3","series-title":"JAMA Netw Open","first-page":"e222246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai MM","year":"2022","unstructured":"Desai MM, Cacciamani GE, Gill K,  Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open 2022;5:e222246."},{"key":"B4","series-title":"JAMA Netw Open","first-page":"e241970","article-title":"Survival in patients with de novo metastatic prostate cancer","volume":"7","author":"Schoen MW","year":"2024","unstructured":"Schoen MW, Bruce Montgomery R, Owens L,  Survival in patients with de novo metastatic prostate cancer. JAMA Netw Open 2024;7:e241970."},{"key":"B5","series-title":"Biomedicines","article-title":"Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Henr\u00edquez I","year":"2021","unstructured":"Henr\u00edquez I, Roach M, Morgan TM,  Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC). Biomedicines 2021;9:1247."},{"key":"B6","series-title":"Prostate Cancer Prostatic Dis","first-page":"327","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland SJ","year":"2024","unstructured":"Freedland SJ, Davis M, Epstein AJ,  Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis 2024;27:327\u2013333."},{"key":"B7","series-title":"J Clin Oncol","first-page":"1402","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher HI","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM,  Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402\u20131418."},{"key":"B8","series-title":"Prostate Cancer Prostatic Dis","article-title":"Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases","volume":"26","author":"Schoen MW","year":"2023","unstructured":"Schoen MW, Carson KR, Eisen SA,  Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis 2023;26:743\u2013750."},{"key":"B9","series-title":"N Engl J Med","first-page":"1995","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono JS","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A,  Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995\u20132005."},{"key":"B10","series-title":"Ther Adv Urol","first-page":"194","article-title":"Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy","volume":"7","author":"Gartrell BA","year":"2015","unstructured":"Gartrell BA, Saad F. Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. Ther Adv Urol 2015;7:194\u2013202."},{"key":"B11","series-title":"N Engl J Med","first-page":"121","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis ID","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR,  Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381:121\u2013131."},{"key":"B12","series-title":"N Engl J Med","first-page":"352","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi K","year":"2017","unstructured":"Fizazi K, Tran N, Fein L,  Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352\u2013360."},{"key":"B13","series-title":"N Engl J Med","first-page":"737","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M,  Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737\u2013746."},{"key":"B14","series-title":"Nat Rev Clin Oncol","first-page":"504","article-title":"The best fit for enzalutamide in metastatic prostate cancer","volume":"11","author":"Pal SK","year":"2014","unstructured":"Pal SK, Sartor O. The best fit for enzalutamide in metastatic prostate cancer. Nat Rev Clin Oncol 2014;11:504\u2013506."},{"key":"B15","series-title":"Prostate Cancer Prostatic Dis","first-page":"800","article-title":"Correction to: survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate","volume":"25","author":"Tagawa ST","year":"2022","unstructured":"Tagawa ST, Ramaswamy K, Huang A,  Correction to: survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis 2022;25:800\u2013801."},{"key":"B16","series-title":"Am J Epidemiol","first-page":"413","article-title":"Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR Cohort)","volume":"190","author":"Scailteux LM","year":"2021","unstructured":"Scailteux LM, Campillo-Gimenez B, Kerbrat S,  Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR Cohort). Am J Epidemiol 2021;190:413\u2013422."},{"key":"B17","article-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2019","author":"Mohler JL","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ,  NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2019. Accessed June 10, 2025. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B18","series-title":"Prostate Cancer","first-page":"8560827","article-title":"Efficacy of abiraterone and enzalutamide in pre- and postdocetaxel castration-resistant prostate cancer: a trial-level meta-analysis","volume":"2017","author":"Fang M","year":"2017","unstructured":"Fang M, Nakazawa M, Antonarakis ES, Li C. Efficacy of abiraterone and enzalutamide in pre- and postdocetaxel castration-resistant prostate cancer: a trial-level meta-analysis. Prostate Cancer 2017;2017:8560827."},{"key":"B19","series-title":"Value Health","first-page":"1259","article-title":"Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic\/mildly symptomatic metastatic castration-resistant prostate cancer","volume":"21","author":"McCool R","year":"2018","unstructured":"McCool R, Fleetwood K, Glanville J,  Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic\/mildly symptomatic metastatic castration-resistant prostate cancer. Value Health 2018;21:1259\u20131268."},{"key":"B20","series-title":"JAMA Oncol","first-page":"326","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger JM","year":"2019","unstructured":"Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol 2019;5:326\u2013333."},{"key":"B21","series-title":"J Clin Oncol","first-page":"1101","article-title":"Disparities in castration-resistant prostate cancer trials","volume":"33","author":"Spratt DE","year":"2015","unstructured":"Spratt DE, Osborne JR. Disparities in castration-resistant prostate cancer trials. J Clin Oncol 2015;33:1101\u20131103."},{"key":"B22","series-title":"JAMA Netw Open","first-page":"e2111516","article-title":"Reporting of participant race, sex, and socioeconomic status in randomized clinical trials in general medical journals, 2015 vs 2019","volume":"4","author":"Alegria M","year":"2021","unstructured":"Alegria M, Sud S, Steinberg BE,  Reporting of participant race, sex, and socioeconomic status in randomized clinical trials in general medical journals, 2015 vs 2019. JAMA Netw Open 2021;4:e2111516."},{"key":"B23","series-title":"J Clin Oncol","first-page":"2639","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard G","year":"2018","unstructured":"Attard G, Borre M, Gurney H,  Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol 2018;36:2639\u20132646."},{"key":"B24","series-title":"N Engl J Med","first-page":"2506","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit R","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN,  Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381:2506\u20132518."},{"key":"B25","series-title":"Ann Oncol","first-page":"1807","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot Y","year":"2013","unstructured":"Loriot Y, Bianchini D, Ileana E,  Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807\u20131812."},{"key":"B26","series-title":"Eur Urol","first-page":"23","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad AA","year":"2015","unstructured":"Azad AA, Eigl BJ, Murray RN,  Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 2015;67:23\u201329."},{"key":"B27","series-title":"Clin Genitourin Cancer","first-page":"142","article-title":"Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"16","author":"Matsubara N","year":"2018","unstructured":"Matsubara N, Yamada Y, Tabata K,  Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2018;16:142\u2013148."},{"key":"B28","series-title":"Prostate","first-page":"33","article-title":"Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study","volume":"77","author":"Maughan BL","year":"2017","unstructured":"Maughan BL, Luber B, Nadal R, Antonarakis ES. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate 2017;77:33\u201340."},{"key":"B29","series-title":"Clin Genitourin Cancer","first-page":"e591","article-title":"Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer","volume":"15","author":"Miyake H","year":"2017","unstructured":"Miyake H, Hara T, Tamura K,  Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2017;15:e591\u2013597."},{"key":"B30","series-title":"Int J Urol","first-page":"441","article-title":"Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-na\u00efve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration","volume":"24","author":"Terada N","year":"2017","unstructured":"Terada N, Maughan BL, Akamatsu S,  Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-na\u00efve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. Int J Urol 2017;24:441\u2013448."},{"key":"B31","series-title":"Lancet Oncol","first-page":"1730","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf DJ","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S,  Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019;20:1730\u20131739."},{"key":"B32","series-title":"CA Cancer J Clin","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel RL","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7\u201333."},{"key":"B33","series-title":"Front Oncol","first-page":"770500","article-title":"Genetic contributions to prostate cancer disparities in men of West African descent","volume":"11","author":"Johnson JR","year":"2021","unstructured":"Johnson JR, Woods-Burnham L, Hooker SE,  Genetic contributions to prostate cancer disparities in men of West African descent. Front Oncol 2021;11:770500."},{"key":"B34","series-title":"Can J Urol","first-page":"3872","article-title":"Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes","volume":"15","author":"Zeigler-Johnson CM","year":"2008","unstructured":"Zeigler-Johnson CM, Spangler E, Jalloh M,  Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can J Urol 2008;15:3872\u20133882."},{"key":"B35","series-title":"Nat Commun","first-page":"8037","article-title":"Prostate cancer genetic risk and associated aggressive disease in men of African ancestry","volume":"14","author":"Soh PXY","year":"2023","unstructured":"Soh PXY, Mmekwa N, Petersen DC,  Prostate cancer genetic risk and associated aggressive disease in men of African ancestry. Nat Commun 2023;14:8037."},{"key":"B36","series-title":"J Urol","first-page":"1408","article-title":"Pathological and biochemical outcomes among African-American and Caucasian men with low risk prostate cancer in the SEARCH database: implications for active surveillance candidacy","volume":"196","author":"Leapman MS","year":"2016","unstructured":"Leapman MS, Freedland SJ, Aronson WJ,  Pathological and biochemical outcomes among African-American and Caucasian men with low risk prostate cancer in the SEARCH database: implications for active surveillance candidacy. J Urol 2016;196:1408\u20131414."},{"key":"B37","series-title":"JAMA Oncol","first-page":"975","article-title":"Association of Black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess RT","year":"2019","unstructured":"Dess RT, Hartman HE, Mahal BA,  Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol 2019;5:975\u2013983."},{"key":"B38","series-title":"JAMA Netw Open","first-page":"e2144027.","article-title":"Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system","volume":"5","author":"Yamoah K","year":"2022","unstructured":"Yamoah K, Lee KM, Awasthi S,  Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system. JAMA Netw Open 2022;5:e2144027."},{"key":"B39","article-title":"Cancer stat facts: prostate cancer","unstructured":"National Cancer Institute. Cancer stat facts: prostate cancer. Accessed June 10, 2025. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"B40","series-title":"Am Soc Clin Oncol Educ Book","first-page":"302","article-title":"All men are created equal: addressing disparities in prostate cancer care","volume":"39","author":"Borno H","year":"2019","unstructured":"Borno H, George DJ, Schnipper LE,  All men are created equal: addressing disparities in prostate cancer care. Am Soc Clin Oncol Educ Book 2019;39:302\u2013308."},{"key":"B41","series-title":"J Clin Oncol","first-page":"403","article-title":"Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi S","year":"2018","unstructured":"Halabi S, Dutta S, Tangen CM,  Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel. J Clin Oncol 2018;37:403\u2013410."},{"key":"B42","series-title":"Prostate Cancer Prostatic Dis","first-page":"524","article-title":"Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer","volume":"25","author":"George DJ","year":"2022","unstructured":"George DJ, Ramaswamy K, Huang A,  Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2022;25:524\u2013530."},{"key":"B43","series-title":"Prostate Cancer Prostatic Dis","first-page":"718","article-title":"Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England","volume":"24","author":"Ng K","year":"2021","unstructured":"Ng K, Wilson P, Mutsvangwa K,  Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England. Prostate Cancer Prostatic Dis 2021;24:718\u2013724."},{"key":"B44","series-title":"JAMA Netw Open","first-page":"e2142093","article-title":"Outcomes among African American and non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone","volume":"5","author":"Marar M","year":"2022","unstructured":"Marar M, Long Q, Mamtani R,  Outcomes among African American and non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw Open 2022;5:e2142093."},{"key":"B45","series-title":"JCO Clin Cancer Inform","first-page":"e2300085.","article-title":"Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer","volume":"7","author":"Candelieri-Surette D","year":"2023","unstructured":"Candelieri-Surette D, Hung A, Lynch JA,  Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer. JCO Clin Cancer Inform 2023;7:e2300085."},{"key":"B46","series-title":"Am J Hum Genet","first-page":"763","article-title":"Harmonizing genetic ancestry and self- identified race\/ethnicity in genome-wide association studies","volume":"105","author":"Fang H","year":"2019","unstructured":"Fang H, Hui Q, Lynch J,  Harmonizing genetic ancestry and self- identified race\/ethnicity in genome-wide association studies. Am J Hum Genet 2019;105:763\u2013772."},{"key":"B47","series-title":"Cancer","first-page":"1290","article-title":"Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards BK","year":"2014","unstructured":"Edwards BK, Noone AM, Mariotto AB,  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120:1290\u20131314."},{"key":"B48","series-title":"JAMA","first-page":"2479","article-title":"Prostate cancer-specific mortality across Gleason scores in Black vs Nonblack men","volume":"320","author":"Mahal BA","year":"2018","unstructured":"Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer-specific mortality across Gleason scores in Black vs Nonblack men. JAMA 2018;320:2479\u20132481."},{"key":"B49","series-title":"Cancer","first-page":"1683","article-title":"Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system","volume":"126","author":"Riviere P","year":"2020","unstructured":"Riviere P, Luterstein E, Kumar A,  Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. Cancer 2020;126:1683\u20131690."},{"key":"B50","series-title":"Cancer","first-page":"3985","article-title":"Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration","volume":"127","author":"Rude T","year":"2021","unstructured":"Rude T, Walter D, Ciprut S,  Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration. Cancer 2021;127:3985\u20133990."},{"key":"B51","series-title":"J Clin Oncol","first-page":"101","article-title":"Survival in Black and non-Black patients with metastatic prostate cancer","volume":"41","author":"Cheranda N","year":"2023","unstructured":"Cheranda N, Luo S, Sanfilippo KM,  Survival in Black and non-Black patients with metastatic prostate cancer. J Clin Oncol 2023;41(Suppl):Abstract 101."},{"key":"B52","article-title":"Oncology Clinical Pathways: Prostate Cancer, V5.2023","unstructured":"US Department of Veterans Affairs. Oncology Clinical Pathways: Prostate Cancer, V5.2023. Accessed November 19, 2025. To view the most recent version, visit https:\/\/www.cancer.va.gov\/clinical-pathways.html"},{"key":"B53","series-title":"Cancers (Basel)","first-page":"3773","article-title":"Outcomes following abiraterone versus enzalutamide for prostate cancer: a scoping review","volume":"14","author":"Shah YB","year":"2022","unstructured":"Shah YB, Shaver AL, Beiriger J,  Outcomes following abiraterone versus enzalutamide for prostate cancer: a scoping review. Cancers (Basel) 2022;14:3773."},{"key":"B54","series-title":"Cancer","first-page":"3608","article-title":"Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer","volume":"122","author":"Kovtun KA","year":"2016","unstructured":"Kovtun KA, Chen MH, Braccioforte MH,  Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. Cancer 2016;122:3608\u20133614."},{"key":"B55","series-title":"J Urol","first-page":"990","article-title":"Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer","volume":"170","author":"Gaston KE","year":"2003","unstructured":"Gaston KE, Kim D, Singh S,  Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 2003;170:990\u2013993."},{"key":"B56","series-title":"Cancer Lett","first-page":"71","article-title":"Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics","volume":"531","author":"Lowder D","year":"2022","unstructured":"Lowder D, Rizwan K, McColl C,  Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics. Cancer Lett 2022;531:71\u201382."},{"key":"B57","series-title":"Urol Oncol","first-page":"418","article-title":"Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate\u2013resistant prostate cancer","volume":"35","author":"Ramalingam S","year":"2017","unstructured":"Ramalingam S, Humeniuk MS, Hu R,  Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate\u2013resistant prostate cancer. Urol Oncol 2017;35:418\u2013424."},{"key":"B58","series-title":"J Natl Med Assoc","first-page":"630","article-title":"Why African Americans may not be participating in clinical trials","volume":"88","author":"Harris Y","year":"1996","unstructured":"Harris Y, Gorelick PB, Samuels P, Bempong I. Why African Americans may not be participating in clinical trials. J Natl Med Assoc 1996;88:630\u2013634."},{"key":"B1","article-title":"Key statistics for prostate cancer.","unstructured":"American Cancer Society. Key statistics for prostate cancer. Accessed June 10, 2025. Available at: https:\/\/www.cancer.org\/cancer\/types\/ prostate-cancer\/about\/key-statistics.html"},{"key":"B2","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"1740","article-title":"Cancer incidence in the U.S. military population: comparison with rates from the SEER program","volume":"18","author":"Zhu K","year":"2009","unstructured":"Zhu K, Devesa SS, Wu H,  Cancer incidence in the U.S. military population: comparison with rates from the SEER program. Cancer Epidemiol Biomarkers Prev 2009;18:1740\u20131745."},{"key":"B3","series-title":"JAMA Netw Open","first-page":"e222246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai MM","year":"2022","unstructured":"Desai MM, Cacciamani GE, Gill K,  Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open 2022;5:e222246."},{"key":"B4","series-title":"JAMA Netw Open","first-page":"e241970","article-title":"Survival in patients with de novo metastatic prostate cancer","volume":"7","author":"Schoen MW","year":"2024","unstructured":"Schoen MW, Bruce Montgomery R, Owens L,  Survival in patients with de novo metastatic prostate cancer. JAMA Netw Open 2024;7:e241970."},{"key":"B5","series-title":"Biomedicines","article-title":"Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Henr\u00edquez I","year":"2021","unstructured":"Henr\u00edquez I, Roach M, Morgan TM,  Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC). Biomedicines 2021;9:1247."},{"key":"B6","series-title":"Prostate Cancer Prostatic Dis","first-page":"327","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland SJ","year":"2024","unstructured":"Freedland SJ, Davis M, Epstein AJ,  Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis 2024;27:327\u2013333."},{"key":"B7","series-title":"J Clin Oncol","first-page":"1402","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher HI","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM,  Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402\u20131418."},{"key":"B8","series-title":"Prostate Cancer Prostatic Dis","article-title":"Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases","volume":"26","author":"Schoen MW","year":"2023","unstructured":"Schoen MW, Carson KR, Eisen SA,  Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis 2023;26:743\u2013750."},{"key":"B9","series-title":"N Engl J Med","first-page":"1995","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono JS","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A,  Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995\u20132005."},{"key":"B10","series-title":"Ther Adv Urol","first-page":"194","article-title":"Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy","volume":"7","author":"Gartrell BA","year":"2015","unstructured":"Gartrell BA, Saad F. Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. Ther Adv Urol 2015;7:194\u2013202."},{"key":"B11","series-title":"N Engl J Med","first-page":"121","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis ID","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR,  Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381:121\u2013131."},{"key":"B12","series-title":"N Engl J Med","first-page":"352","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi K","year":"2017","unstructured":"Fizazi K, Tran N, Fein L,  Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352\u2013360."},{"key":"B13","series-title":"N Engl J Med","first-page":"737","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M,  Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737\u2013746."},{"key":"B14","series-title":"Nat Rev Clin Oncol","first-page":"504","article-title":"The best fit for enzalutamide in metastatic prostate cancer","volume":"11","author":"Pal SK","year":"2014","unstructured":"Pal SK, Sartor O. The best fit for enzalutamide in metastatic prostate cancer. Nat Rev Clin Oncol 2014;11:504\u2013506."},{"key":"B15","series-title":"Prostate Cancer Prostatic Dis","first-page":"800","article-title":"Correction to: survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate","volume":"25","author":"Tagawa ST","year":"2022","unstructured":"Tagawa ST, Ramaswamy K, Huang A,  Correction to: survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis 2022;25:800\u2013801."},{"key":"B16","series-title":"Am J Epidemiol","first-page":"413","article-title":"Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR Cohort)","volume":"190","author":"Scailteux LM","year":"2021","unstructured":"Scailteux LM, Campillo-Gimenez B, Kerbrat S,  Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR Cohort). Am J Epidemiol 2021;190:413\u2013422."},{"key":"B17","article-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2019","author":"Mohler JL","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ,  NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2019. Accessed June 10, 2025. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B18","series-title":"Prostate Cancer","first-page":"8560827","article-title":"Efficacy of abiraterone and enzalutamide in pre- and postdocetaxel castration-resistant prostate cancer: a trial-level meta-analysis","volume":"2017","author":"Fang M","year":"2017","unstructured":"Fang M, Nakazawa M, Antonarakis ES, Li C. Efficacy of abiraterone and enzalutamide in pre- and postdocetaxel castration-resistant prostate cancer: a trial-level meta-analysis. Prostate Cancer 2017;2017:8560827."},{"key":"B19","series-title":"Value Health","first-page":"1259","article-title":"Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic\/mildly symptomatic metastatic castration-resistant prostate cancer","volume":"21","author":"McCool R","year":"2018","unstructured":"McCool R, Fleetwood K, Glanville J,  Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic\/mildly symptomatic metastatic castration-resistant prostate cancer. Value Health 2018;21:1259\u20131268."},{"key":"B20","series-title":"JAMA Oncol","first-page":"326","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger JM","year":"2019","unstructured":"Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol 2019;5:326\u2013333."},{"key":"B21","series-title":"J Clin Oncol","first-page":"1101","article-title":"Disparities in castration-resistant prostate cancer trials","volume":"33","author":"Spratt DE","year":"2015","unstructured":"Spratt DE, Osborne JR. Disparities in castration-resistant prostate cancer trials. J Clin Oncol 2015;33:1101\u20131103."},{"key":"B22","series-title":"JAMA Netw Open","first-page":"e2111516","article-title":"Reporting of participant race, sex, and socioeconomic status in randomized clinical trials in general medical journals, 2015 vs 2019","volume":"4","author":"Alegria M","year":"2021","unstructured":"Alegria M, Sud S, Steinberg BE,  Reporting of participant race, sex, and socioeconomic status in randomized clinical trials in general medical journals, 2015 vs 2019. JAMA Netw Open 2021;4:e2111516."},{"key":"B23","series-title":"J Clin Oncol","first-page":"2639","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard G","year":"2018","unstructured":"Attard G, Borre M, Gurney H,  Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol 2018;36:2639\u20132646."},{"key":"B24","series-title":"N Engl J Med","first-page":"2506","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit R","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN,  Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381:2506\u20132518."},{"key":"B25","series-title":"Ann Oncol","first-page":"1807","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot Y","year":"2013","unstructured":"Loriot Y, Bianchini D, Ileana E,  Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807\u20131812."},{"key":"B26","series-title":"Eur Urol","first-page":"23","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad AA","year":"2015","unstructured":"Azad AA, Eigl BJ, Murray RN,  Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 2015;67:23\u201329."},{"key":"B27","series-title":"Clin Genitourin Cancer","first-page":"142","article-title":"Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"16","author":"Matsubara N","year":"2018","unstructured":"Matsubara N, Yamada Y, Tabata K,  Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2018;16:142\u2013148."},{"key":"B28","series-title":"Prostate","first-page":"33","article-title":"Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study","volume":"77","author":"Maughan BL","year":"2017","unstructured":"Maughan BL, Luber B, Nadal R, Antonarakis ES. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate 2017;77:33\u201340."},{"key":"B29","series-title":"Clin Genitourin Cancer","first-page":"e591","article-title":"Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer","volume":"15","author":"Miyake H","year":"2017","unstructured":"Miyake H, Hara T, Tamura K,  Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2017;15:e591\u2013597."},{"key":"B30","series-title":"Int J Urol","first-page":"441","article-title":"Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-na\u00efve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration","volume":"24","author":"Terada N","year":"2017","unstructured":"Terada N, Maughan BL, Akamatsu S,  Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-na\u00efve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. Int J Urol 2017;24:441\u2013448."},{"key":"B31","series-title":"Lancet Oncol","first-page":"1730","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf DJ","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S,  Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019;20:1730\u20131739."},{"key":"B32","series-title":"CA Cancer J Clin","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel RL","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7\u201333."},{"key":"B33","series-title":"Front Oncol","first-page":"770500","article-title":"Genetic contributions to prostate cancer disparities in men of West African descent","volume":"11","author":"Johnson JR","year":"2021","unstructured":"Johnson JR, Woods-Burnham L, Hooker SE,  Genetic contributions to prostate cancer disparities in men of West African descent. Front Oncol 2021;11:770500."},{"key":"B34","series-title":"Can J Urol","first-page":"3872","article-title":"Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes","volume":"15","author":"Zeigler-Johnson CM","year":"2008","unstructured":"Zeigler-Johnson CM, Spangler E, Jalloh M,  Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can J Urol 2008;15:3872\u20133882."},{"key":"B35","series-title":"Nat Commun","first-page":"8037","article-title":"Prostate cancer genetic risk and associated aggressive disease in men of African ancestry","volume":"14","author":"Soh PXY","year":"2023","unstructured":"Soh PXY, Mmekwa N, Petersen DC,  Prostate cancer genetic risk and associated aggressive disease in men of African ancestry. Nat Commun 2023;14:8037."},{"key":"B36","series-title":"J Urol","first-page":"1408","article-title":"Pathological and biochemical outcomes among African-American and Caucasian men with low risk prostate cancer in the SEARCH database: implications for active surveillance candidacy","volume":"196","author":"Leapman MS","year":"2016","unstructured":"Leapman MS, Freedland SJ, Aronson WJ,  Pathological and biochemical outcomes among African-American and Caucasian men with low risk prostate cancer in the SEARCH database: implications for active surveillance candidacy. J Urol 2016;196:1408\u20131414."},{"key":"B37","series-title":"JAMA Oncol","first-page":"975","article-title":"Association of Black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess RT","year":"2019","unstructured":"Dess RT, Hartman HE, Mahal BA,  Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol 2019;5:975\u2013983."},{"key":"B38","series-title":"JAMA Netw Open","first-page":"e2144027.","article-title":"Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system","volume":"5","author":"Yamoah K","year":"2022","unstructured":"Yamoah K, Lee KM, Awasthi S,  Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system. JAMA Netw Open 2022;5:e2144027."},{"key":"B39","article-title":"Cancer stat facts: prostate cancer","unstructured":"National Cancer Institute. Cancer stat facts: prostate cancer. Accessed June 10, 2025. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"B40","series-title":"Am Soc Clin Oncol Educ Book","first-page":"302","article-title":"All men are created equal: addressing disparities in prostate cancer care","volume":"39","author":"Borno H","year":"2019","unstructured":"Borno H, George DJ, Schnipper LE,  All men are created equal: addressing disparities in prostate cancer care. Am Soc Clin Oncol Educ Book 2019;39:302\u2013308."},{"key":"B41","series-title":"J Clin Oncol","first-page":"403","article-title":"Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi S","year":"2018","unstructured":"Halabi S, Dutta S, Tangen CM,  Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel. J Clin Oncol 2018;37:403\u2013410."},{"key":"B42","series-title":"Prostate Cancer Prostatic Dis","first-page":"524","article-title":"Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer","volume":"25","author":"George DJ","year":"2022","unstructured":"George DJ, Ramaswamy K, Huang A,  Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2022;25:524\u2013530."},{"key":"B43","series-title":"Prostate Cancer Prostatic Dis","first-page":"718","article-title":"Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England","volume":"24","author":"Ng K","year":"2021","unstructured":"Ng K, Wilson P, Mutsvangwa K,  Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England. Prostate Cancer Prostatic Dis 2021;24:718\u2013724."},{"key":"B44","series-title":"JAMA Netw Open","first-page":"e2142093","article-title":"Outcomes among African American and non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone","volume":"5","author":"Marar M","year":"2022","unstructured":"Marar M, Long Q, Mamtani R,  Outcomes among African American and non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw Open 2022;5:e2142093."},{"key":"B45","series-title":"JCO Clin Cancer Inform","first-page":"e2300085.","article-title":"Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer","volume":"7","author":"Candelieri-Surette D","year":"2023","unstructured":"Candelieri-Surette D, Hung A, Lynch JA,  Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer. JCO Clin Cancer Inform 2023;7:e2300085."},{"key":"B46","series-title":"Am J Hum Genet","first-page":"763","article-title":"Harmonizing genetic ancestry and self- identified race\/ethnicity in genome-wide association studies","volume":"105","author":"Fang H","year":"2019","unstructured":"Fang H, Hui Q, Lynch J,  Harmonizing genetic ancestry and self- identified race\/ethnicity in genome-wide association studies. Am J Hum Genet 2019;105:763\u2013772."},{"key":"B47","series-title":"Cancer","first-page":"1290","article-title":"Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards BK","year":"2014","unstructured":"Edwards BK, Noone AM, Mariotto AB,  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120:1290\u20131314."},{"key":"B48","series-title":"JAMA","first-page":"2479","article-title":"Prostate cancer-specific mortality across Gleason scores in Black vs Nonblack men","volume":"320","author":"Mahal BA","year":"2018","unstructured":"Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer-specific mortality across Gleason scores in Black vs Nonblack men. JAMA 2018;320:2479\u20132481."},{"key":"B49","series-title":"Cancer","first-page":"1683","article-title":"Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system","volume":"126","author":"Riviere P","year":"2020","unstructured":"Riviere P, Luterstein E, Kumar A,  Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. Cancer 2020;126:1683\u20131690."},{"key":"B50","series-title":"Cancer","first-page":"3985","article-title":"Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration","volume":"127","author":"Rude T","year":"2021","unstructured":"Rude T, Walter D, Ciprut S,  Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration. Cancer 2021;127:3985\u20133990."},{"key":"B51","series-title":"J Clin Oncol","first-page":"101","article-title":"Survival in Black and non-Black patients with metastatic prostate cancer","volume":"41","author":"Cheranda N","year":"2023","unstructured":"Cheranda N, Luo S, Sanfilippo KM,  Survival in Black and non-Black patients with metastatic prostate cancer. J Clin Oncol 2023;41(Suppl):Abstract 101."},{"key":"B52","article-title":"Oncology Clinical Pathways: Prostate Cancer, V5.2023","unstructured":"US Department of Veterans Affairs. Oncology Clinical Pathways: Prostate Cancer, V5.2023. Accessed November 19, 2025. To view the most recent version, visit https:\/\/www.cancer.va.gov\/clinical-pathways.html"},{"key":"B53","series-title":"Cancers (Basel)","first-page":"3773","article-title":"Outcomes following abiraterone versus enzalutamide for prostate cancer: a scoping review","volume":"14","author":"Shah YB","year":"2022","unstructured":"Shah YB, Shaver AL, Beiriger J,  Outcomes following abiraterone versus enzalutamide for prostate cancer: a scoping review. Cancers (Basel) 2022;14:3773."},{"key":"B54","series-title":"Cancer","first-page":"3608","article-title":"Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer","volume":"122","author":"Kovtun KA","year":"2016","unstructured":"Kovtun KA, Chen MH, Braccioforte MH,  Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. Cancer 2016;122:3608\u20133614."},{"key":"B55","series-title":"J Urol","first-page":"990","article-title":"Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer","volume":"170","author":"Gaston KE","year":"2003","unstructured":"Gaston KE, Kim D, Singh S,  Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 2003;170:990\u2013993."},{"key":"B56","series-title":"Cancer Lett","first-page":"71","article-title":"Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics","volume":"531","author":"Lowder D","year":"2022","unstructured":"Lowder D, Rizwan K, McColl C,  Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics. Cancer Lett 2022;531:71\u201382."},{"key":"B57","series-title":"Urol Oncol","first-page":"418","article-title":"Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate\u2013resistant prostate cancer","volume":"35","author":"Ramalingam S","year":"2017","unstructured":"Ramalingam S, Humeniuk MS, Hu R,  Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate\u2013resistant prostate cancer. Urol Oncol 2017;35:418\u2013424."},{"key":"B58","series-title":"J Natl Med Assoc","first-page":"630","article-title":"Why African Americans may not be participating in clinical trials","volume":"88","author":"Harris Y","year":"1996","unstructured":"Harris Y, Gorelick PB, Samuels P, Bempong I. Why African Americans may not be participating in clinical trials. J Natl Med Assoc 1996;88:630\u2013634."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/12\/article-p507.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/12\/article-p507.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/12\/article-p507.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:56:22Z","timestamp":1765979782000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/12\/article-p507.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":116,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7078","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}